NCT06701357View on ClinicalTrials.gov

CR-CHOP+X in Previously Untreated DEL

PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2028

Conditions
DLBCL
Interventions
DRUG

CR-CHOP+PD1 inhibitor

Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； PD1 200mg D1

DRUG

CR-CHOP + Orelabrutinib

Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Orelabrutinib 150mg/qd D1-21

DRUG

CR-CHOP + decitabine

Rituximab 375 mg/m2 D1； Cyclophosphamide 750mg/m2 D2； Doxorubicin 50mg/m2 D2； Vincristine 1.4 mg/m2 D2； Prednisone 60 mg/m2 D2-6； Chidamide 20mg/d D1,4,8,11； Decitabine 10mg/m2 D-5 - -1

Trial Locations (1)

Unknown

RECRUITING

No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER